CN106999539A - 腹水的治疗 - Google Patents

腹水的治疗 Download PDF

Info

Publication number
CN106999539A
CN106999539A CN201680003239.1A CN201680003239A CN106999539A CN 106999539 A CN106999539 A CN 106999539A CN 201680003239 A CN201680003239 A CN 201680003239A CN 106999539 A CN106999539 A CN 106999539A
Authority
CN
China
Prior art keywords
terlipressin
ascites
patient
continuous infusion
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680003239.1A
Other languages
English (en)
Chinese (zh)
Inventor
P.昂厄利
P.马卡姆
J.阿达姆斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biovie Inc
Original Assignee
Nanoantibiotics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57609113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN106999539(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nanoantibiotics Inc filed Critical Nanoantibiotics Inc
Priority to CN202510468211.6A priority Critical patent/CN120324576A/zh
Publication of CN106999539A publication Critical patent/CN106999539A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
CN201680003239.1A 2015-06-30 2016-06-30 腹水的治疗 Pending CN106999539A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510468211.6A CN120324576A (zh) 2015-06-30 2016-06-30 腹水的治疗

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562186638P 2015-06-30 2015-06-30
US62/186,638 2015-06-30
US201562267510P 2015-12-15 2015-12-15
US62/267,510 2015-12-15
US201662321558P 2016-04-12 2016-04-12
US62/321,558 2016-04-12
PCT/US2016/040284 WO2017004317A1 (en) 2015-06-30 2016-06-30 Treatment of ascites

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510468211.6A Division CN120324576A (zh) 2015-06-30 2016-06-30 腹水的治疗

Publications (1)

Publication Number Publication Date
CN106999539A true CN106999539A (zh) 2017-08-01

Family

ID=57609113

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510468211.6A Pending CN120324576A (zh) 2015-06-30 2016-06-30 腹水的治疗
CN201680003239.1A Pending CN106999539A (zh) 2015-06-30 2016-06-30 腹水的治疗

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202510468211.6A Pending CN120324576A (zh) 2015-06-30 2016-06-30 腹水的治疗

Country Status (7)

Country Link
US (6) US9655945B2 (2)
EP (2) EP3347032B1 (2)
JP (6) JP2017014206A (2)
CN (2) CN120324576A (2)
ES (1) ES2971959T3 (2)
HK (1) HK1258611A1 (2)
WO (1) WO2017004317A1 (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112704727A (zh) * 2021-01-12 2021-04-27 重庆医科大学附属第二医院 特利加压素在制备动力性肠梗阻药物中的应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101814186B1 (ko) 2008-09-17 2018-03-14 키아스마 인코포레이티드 약제학적 조성물 및 연관된 투여방법
US10335452B2 (en) 2014-10-24 2019-07-02 Mallinckrodt Hospital Products IP Limited Method of treating patients with hepatorenal syndrome type 1
WO2016126830A1 (en) 2015-02-03 2016-08-11 Chiasma Inc. Method of treating diseases
JP2017014206A (ja) * 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療
IL313083A (en) 2016-10-21 2024-07-01 Amryt Endo Inc Terlipressin compositions and their methods of use
CN113077888A (zh) * 2021-03-30 2021-07-06 福州宜星大数据产业投资有限公司 自动化meld评分方法、终端及存储介质
JP2025505010A (ja) * 2022-02-03 2025-02-19 バイオビー インコーポレーテッド テルリプレシンを用いた疾患の治療方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024213A2 (en) * 2000-09-15 2002-03-28 Inserm Improved protocol for paracentesis
US20110300109A1 (en) * 2008-08-26 2011-12-08 Kyon Biotech Ag Compositions and methods for treating cancer
CN102731625A (zh) * 2012-06-27 2012-10-17 深圳翰宇药业股份有限公司 一种纯化特利加压素的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1984012T3 (en) * 2006-02-13 2016-03-29 Ferring Bv USE OF peptidic vasopressin receptor agonists
WO2009037586A2 (en) * 2007-08-14 2009-03-26 Ferring B.V. Use of peptidic vasopressin receptor agonists
EP2203172A2 (en) * 2007-09-28 2010-07-07 Ferring B.V. Use of v2 receptor antagonists in combination with vasopressinergic agonists
WO2009062174A1 (en) * 2007-11-08 2009-05-14 University Of Utah Research Foundation Use of angiogenesis antagonists in conditions of abnormal venous proliferation
CN102369296A (zh) * 2009-03-09 2012-03-07 生物蛋白有限公司 Mirac蛋白
CN104434894A (zh) * 2009-06-08 2015-03-25 Ucl商业有限公司 使用l-鸟氨酸苯乙酸盐治疗门静脉高压和恢复肝功能
KR20130026504A (ko) * 2010-07-14 2013-03-13 큠버랜드 에멀징 테크놀로지스 아이앤씨 트롬복산-a2 수용체 길항제를 이용한 간신증후군 및 간성뇌증의 치료방법
WO2013106072A1 (en) 2012-01-10 2013-07-18 Sorbent Therapeutics, Inc. Compositions comprising crosslinked cation-binding polymers and uses thereof
JO3109B1 (ar) * 2012-05-10 2017-09-20 Ferring Bv منبهات لمستقبلات v1a
CA2891281C (en) * 2012-11-12 2023-11-28 The Regents Of The University Of Colorado, A Body Corporate Disease severity index for assessment of chronic liver disease and method for diagnosis of three distinct subtypes of primary sclerosing cholangitis
EP2988770A4 (en) * 2013-04-26 2016-12-14 La Jolla Pharma Co COMPOSITIONS AND METHOD FOR TREATING KIDNEY FAILURES
US20150056194A1 (en) * 2013-08-21 2015-02-26 Georgia Regents Research Institute, Inc. Modified green tea polyphenols and methods thereof for treating liver disease
JP2017014206A (ja) * 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024213A2 (en) * 2000-09-15 2002-03-28 Inserm Improved protocol for paracentesis
US20040102362A1 (en) * 2000-09-15 2004-05-27 Didier Lebrec Protocol for paracentesis
US20110300109A1 (en) * 2008-08-26 2011-12-08 Kyon Biotech Ag Compositions and methods for treating cancer
CN102731625A (zh) * 2012-06-27 2012-10-17 深圳翰宇药业股份有限公司 一种纯化特利加压素的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALEKSANDER KRAG等: ""Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome"", 《HEPATOLOGY》 *
MARCUS ROBERTSON等: ""Continuous outpatient terlipressin infusion for hepatorenal syndrome as a bridge to successful liver transplantation"", 《HEPATOLOGY》 *
PAOLO ANGELI: ""Terlipressin for the treatment of hepatorenal syndrome in patients with cirrhosis"", 《EXPERT OPINION ON ORPHAN DRUGS》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112704727A (zh) * 2021-01-12 2021-04-27 重庆医科大学附属第二医院 特利加压素在制备动力性肠梗阻药物中的应用
CN112704727B (zh) * 2021-01-12 2023-05-16 重庆医科大学附属第二医院 特利加压素在制备动力性肠梗阻药物中的应用

Also Published As

Publication number Publication date
EP3347032B1 (en) 2023-11-29
US20240165193A1 (en) 2024-05-23
EP3347032A4 (en) 2019-06-19
JP2020172520A (ja) 2020-10-22
CN120324576A (zh) 2025-07-18
JP2022136104A (ja) 2022-09-15
ES2971959T3 (es) 2024-06-10
WO2017004317A1 (en) 2017-01-05
US20190365848A1 (en) 2019-12-05
HK1258611A1 (zh) 2019-11-15
JP2025143324A (ja) 2025-10-01
US20170000844A1 (en) 2017-01-05
US9655945B2 (en) 2017-05-23
US11364277B2 (en) 2022-06-21
EP4338795A2 (en) 2024-03-20
JP2023160839A (ja) 2023-11-02
US20230146264A1 (en) 2023-05-11
JP2017014206A (ja) 2017-01-19
US20180000887A1 (en) 2018-01-04
EP4338795A3 (en) 2024-08-28
US20250312410A1 (en) 2025-10-09
EP3347032A1 (en) 2018-07-18
JP2018172440A (ja) 2018-11-08

Similar Documents

Publication Publication Date Title
CN106999539A (zh) 腹水的治疗
Nakayama et al. Novel therapeutic option for refractory heart failure in elderly patients with chronic kidney disease by incremental peritoneal dialysis
JP2022028813A (ja) 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
JP2018531605A5 (2)
JP2020510043A5 (2)
Saraceno et al. Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two cases
CN102552121B (zh) 一种米力农注射液
CN114796246B (zh) 一种用于治疗心力衰竭的药物及其用途
CN104688766B (zh) 注射用藻酸双酯钠粉针剂药物组合物和制法
RU2406539C2 (ru) Способ лечения хронической почечной недостаточности
CN1064234C (zh) 二咖啡酰氧基--奎宁酸在制药中的应用
Poca et al. 104 RENAL FAILURE AND MORTALITY IN CIRRHOTIC PATIENTS WITH SPONTANEOUS BACTERIAL PERITONITIS AND LOW RISK OF MORTALITY NON-TREATED WITH ALBUMIN
Zhao A Case Analysis of Antihypertensive Treatment in a Patient Undergoing CRRT with Comorbid Coronary Heart Disease
WO2016139740A1 (ja) 肝線維化改善剤
Mckellar et al. Hyperkalaemia: causes, electrocardiographic changes and management
Knyazkova et al. Efficiency of torasemide in heart failure in patients with ischemic heart disease and chronic obstructive pulmonary disease
US20170007617A1 (en) Intravenous formulations of a late sodium current inhibitor
Alessandria et al. 103 RELATIVE ADRENAL INSUFFICIENCY IN CIRRHOSIS: RELEVANCE IN PATIENTS WITH ASCITES AND TREATMENT WITH HYDROCORTISONE IN REFRACTORY ASCITES
CN103285378A (zh) Glp-1用于制备预防与治疗2型糖尿病性心肌病的药物的用途
Li Application of albumin in liver cirrhosis and its complications
CN102579325A (zh) 乙烷硒啉静脉注射剂
Hurley After SCI, Short Sleep Duration Raises Stroke Risk
CN107970248A (zh) 异甘草酸在制备治疗高血压药物中的用途
JP2018104292A (ja) マグネシウム化合物を有効成分とする医薬組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20170801

RJ01 Rejection of invention patent application after publication